CXCR4 antagonist AMD3100 enhances therapeutic efficacy of transcatheter arterial chemoembolization in rats with hepatocellular carcinoma

Hong‐Wei Lei,Bi‐Run Huang,Jie Cai,Cheng‐Ming Li,Chun‐Bo Shang,Zhi‐Yang Liao,Zheng‐Dong Wan

DOI: https://doi.org/10.1002/kjm2.12540

2022-04-25

The Kaohsiung Journal of Medical Sciences

Abstract:The Kaohsiung Journal of Medical Sciences, Volume 38, Issue 8, Page 781-789, August 2022.

What problem does this paper attempt to address?

Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist AMD3100 in a Mouse Transplantation Model

Yubin Kang,Benny J. Chen,Divino DeOliveira,Jeffrey Mito,Nelson J. Chao

DOI: https://doi.org/10.1371/journal.pone.0011316

IF: 3.7

2010-06-28

PLoS ONE

Abstract:The interaction between stromal cell-derived factor-1 (SDF-1) with CXCR4 chemokine receptors plays an important role in hematopoiesis following hematopoietic stem cell transplantation. We examined the efficacy of post transplant administration of a specific CXCR4 antagonist (AMD3100) in improving animal survival and in enhancing donor hematopoietic cell engraftment using a congeneic mouse transplantation model. AMD3100 was administered subcutaneously at 5 mg/kg body weight 3 times a week beginning at day +2 post-transplant. Post-transplant administration of AMD3100 significantly improves animal survival. AMD3100 reduces pro-inflammatory cytokine/chemokine production. Furthermore, post transplant administration of AMD3100 selectively enhances donor cell engraftment and promotes recovery of all donor cell lineages (myeloid cells, T and B lymphocytes, erythrocytes and platelets). This enhancement results from a combined effect of increased marrow niche availability and greater cell division induced by AMD3100. Our studies shed new lights into the biological roles of SDF-1/CXCR4 interaction in hematopoietic stem cell engraftment following transplantation and in transplant-related mortality. Our results indicate that AMD3100 provides a novel approach for enhancing hematological recovery following transplantation, and will likely benefit patients undergoing transplantation.

multidisciplinary sciences
Enhanced Efficacy of Direct Immunochemotherapy for Hepatic Cancer with Image-Guided Intratumoral Radiofrequency Hyperthermia

Xuefeng Kan,Guanhui Zhou,Feng Zhang,Hongxiu Ji,David S. Shin,Wayne Monsky,Chuansheng Zheng,Xiaoming Yang

DOI: https://doi.org/10.1136/jitc-2022-005619

IF: 12.469

2022-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Background It is still a challenge to prevent tumor recurrence post radiofrequency ablation (RFA) of medium-to-large hepatocellular carcinomas (HCC). Immunochemotherapy, a combination of immunotherapy with chemotherapy, has demonstrated a great potential in augmenting the treatment efficacy for some malignancies. In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC.Methods Different groups of luciferase-labeled rat HCC cells and rat orthotopic HCC models were treated by: (1) phosphate buffered saline; (2) RFH; (3) LTX-315; (4) RFH+LTX-315; (5) liposomal doxorubicin; (6) RFH+liposomal doxorubicin; (7) LTX-315+liposomal doxorubicin; and (8) RFH+LTX-315+liposomal doxorubicin. Cell viabilities and apoptosis of different treatment groups were compared. Changes in tumor sizes were quantified by optical and ultrasound imaging, which were confirmed by subsequent histopathology. The potential underlying biological mechanisms of the triple combination treatment (RFH+LTX-315+liposomal doxorubicin) were explored.Results Flow cytometry and MTS assay showed the highest percentage of apoptotic cells and lowest cell viability in the triple combination treatment group compared with other seven groups (p<0.001). Tumors in this group also presented the most profound decrease in bioluminescence signal intensities and the smallest tumor volumes compared with other seven groups (p<0.001). A significant increase of CD8+ T cells, CD8+/interferon (IFN)-γ+ T cells, CD8+/tumor necrosis factor (TNF)-α+ T cells, and natural killer cells, and a significant decrease of regulatory T cells were observed in the tumors (p<0.001). Meanwhile, a significantly higher level of Th1-type cytokines in both plasma (interleukin (IL)-2, IL-12, IL-18, IFN-γ) and tumors (IL-2, IL-18, IFN-γ, TNF-α), as well as a significantly lower Th2-type cytokines of IL-4 and IL-10 in plasma and tumor were detected.Conclusions Intratumoral RFA-associated RFH could enhance the efficacy of immunochemotherapy of LTX-315 with liposomal doxorubicin for HCC, which may provide a new strategy to increase the curative efficacy of thermal ablation for medium-to-large HCC.
Effect of inhibit or AMD3100 of CXCR4 on liver metastasis of colorectal cancer

Chun-kang YANG,Chen-xing JIAN,Min-gang YING

DOI: https://doi.org/10.16073/j.cnki.cjcpt.2010.18.017

2010-01-01

Abstract:OBJECTIVE, To investigate the inhibition of the specific CXCR4 antagonist AMD3100 in colorectal carcinoma liver metastasis and explore its control mechanism in vivo. METHODS: A mouse model of colorectal cancer liver metastasis was established by splenectomy technique. The 18 nude mice were randomly divided into 3 groups, a control group (0.1 mL saline solution), treatment group of low dose AMD3100 (4 mg/kg ) and treatment group of high dose AMD3100(6 mg/kg) . Six weeks after implantation,the differences of liver metastasis among the groups were compared. RESULTS: The diameters of the spleen primary tumors were (13. 83±7. 73) mm(the control group),(5. 17±0.75) mm(the treatment group of low dose AMD3100)and (2.83±1.33) mm (the treatment group of high dose AMD3100) respectively (P<0. 05); and the diameters of the liver metastasis were (3.42±2. 24) mm,(2.26±1.12) mm and (1.62±0.88) mm respectively (P<0.05); numbers of the liver metastasis were 21.00±3. 90, 13.00±1.79 and 2.17±1.37 respectively (P< 0.05). CONCLUSIONS: The specific CXCR4 antagonist AMD3100 greatly affects the development of liver metastasis in colorectal cancer. It can inhibit the growth of the liver metastasis tumor in colorectal carcinoma and it is more effective of the high dose than of the low dose in the experiment.
CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation

Jun Zhou,Kehao Le,Ming Xu,Jie Ming,Wen Yang,Qiulei Zhang,Linlin Lu,Zihan Xi,Shengnan Ruan,Tao Huang

DOI: https://doi.org/10.1016/j.omto.2020.06.009

2020-09-01

Abstract:Endocrine therapy is a systemic therapy and has become the main treatment strategy for patients with estrogen receptor (ER) positive breast cancer. However, tamoxifen resistance has become an insurmountable clinical challenge and the underlying mechanisms are still poorly understood. In this study, we explored the roles of CXCR4 in tamoxifen-treated breast cancer and tamoxifen resistance. Based on Gene Expression Omnibus (GEO) database, high expression of CXCR4 was found to be associated with worse overall survival (HR = 4.646, p < 0.001) and cancer-specific survival (HR = 4.480, p < 0.001) in tamoxifen-treated breast cancer. CXCR4 was also positively correlated with the level of AKT phosphorylation and the resistance to tamoxifen in breast cancer. AMD3100 is a CXCR4 antagonist and was found to decrease p-AKT levels of tamoxifen-resistant cells. The reversal effect of AMD3100 on tamoxifen resistance was also confirmed in vitro and in vivo. Taken together, our study demonstrated that CXCR4 could be a potential prognostic biomarker for tamoxifen-treated breast cancer and the combination of AMD3100 with tamoxifen could be a more efficacious therapeutic strategy for the treatment of tamoxifen resistance.
Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models

Da-Yong Zhou,Jie Qin,Jian Huang,Feng Wang,Guo-Peng Xu,Yan-Tian Lv,Ji-Bin Zhang,Li-Ming Shen

DOI: https://doi.org/10.3892/ol.2017.6717

2017-08-03

Oncology Letters

Abstract:Hepatic transcatheter arterial chemoembolization (TACE), a minimally invasive procedure to block the blood supply of tumors and release of cytotoxic agents, is preferentially applied to patients with hepatocellular carcinoma (HCC) who are not able to receive radical treatments. However, the long-term effects of TACE are unsatisfactory, as the microenvironment following procedure stimulates tumor angiogenesis, which promotes recurrence and metastasis of residual tumors. Tumor associated macrophages (TAMs) have been revealed to stimulate tumor growth and angiogenesis associated with poor prognosis in HCC. The present study focused on the changes in TAMs following TACE, and explored the effects of TACE in combination with the TAM inhibitor zoledronic acid (ZA) in rat HCC models. Orthotropic HCC rats were divided into three groups: Sham TACE, TACE alone and TACE combined with ZA treatment. At 7 or 14 days following TACE, tumor growth was evaluated by magnetic resonance imaging (MRI). Infiltration of TAMs was assessed by histological analysis and flow cytometry. Tumor angiogenesis was measured as the mean vessel density, and initial slope was calculated from dynamic contrast enhancement MRI. Local and systemic levels of vascular endothelial growth factor (VEGF) were determined by western blotting or an ELISA, respectively. The results revealed that TACE inhibited tumor growth at 7 days following the procedure, but this inhibition was attenuated at 14 days following the procedure compared with the sham TACE control. If combined with ZA treatment, TACE exhibited a stable inhibition effect on tumor growth until the end of observation. Investigation of the underlying mechanisms demonstrated that TACE combined with ZA treatment inhibited infiltration of F4/80 positive TAMs and tumor angiogenesis compared with the TACE alone group at 14 days following the procedure. Additionally, the combination treatment significantly inhibited secretion of VEGF in the present models. In conclusion, ZA treatment enhanced the effects of TACE through inhibiting TAM infiltration and tumor angiogenesis in rat HCC models.

oncology
AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression

Binghao Li,Yang Zeng,Patrick M Reeves,Chongzhao Ran,Qiuyan Liu,Xiying Qu,Yingying Liang,Zhao Liu,Jianping Yuan,Pierre R Leblanc,Zhaoming Ye,Ann E Sluder,Jeffrey A Gelfand,Timothy A Brauns,Huabiao Chen,Mark C Poznansky

DOI: https://doi.org/10.1158/2326-6066.CIR-17-0530

Abstract:AMD3100 (plerixafor), a CXCR4 antagonist, has been demonstrated to suppress tumor growth and modulate intratumoral T-cell trafficking. However, the effect of AMD3100 on immunomodulation remains elusive. Here, we explored immunomodulation and antitumor efficacy of AMD3100 in combination with a previously developed mesothelin-targeted, immune-activating fusion protein, VIC-008, in two syngeneic, orthotopic models of malignant mesothelioma in immunocompetent mice. We showed that combination therapy significantly suppressed tumor growth and prolonged animal survival in two mouse models. Tumor control and survival benefit were associated with enhanced antitumor immunity. VIC-008 augmented mesothelin-specific CD8+ T-cell responses in the spleen and lymph nodes and facilitated intratumoral lymphocytic infiltration. However, VIC-008 treatment was associated with increased programmed cell death protein-1 (PD-1) expression on intratumoral CD8+ T cells, likely due to high CXCL12 in the tumor microenvironment. AMD3100 alone and in combination with VIC-008 modulated immunosuppression in tumors and the immune system through suppression of PD-1 expression on CD8+ T cells and conversion of regulatory T cells (Tregs) into CD4+CD25-Foxp3+IL2+CD40L+ helper-like cells. In mechanistic studies, we demonstrated that AMD3100-driven Treg reprogramming required T cell receptor (TCR) activation and was associated with loss of PTEN due to oxidative inactivation. The combination of VIC-008 augmentation of tumor-specific CD8+ T-cell responses with AMD3100 abrogation of immunosuppression conferred significant benefits for tumor control and animal survival. These data provide new mechanistic insight into AMD3100-mediated immunomodulation and highlight the enhanced antitumor effect of AMD3100 in combination with a tumor antigen-targeted therapy in mouse malignant mesothelioma, which could be clinically relevant to patients with this difficult-to-treat disease. Cancer Immunol Res; 6(5); 539-51. ©2018 AACR.
[Serum cholylglycine in the evaluation of impaired hepatic function].

A. Salmi,G. Pizzoccolo,P. Uccelli,A. Paterlini,R. Moretti

1986-04-21

Minerva Medica

Abstract:The biliary serum salts cholylglycine and sulfolithocholylglycine were assessed in 88 chronic liver disease patients subjected to laparoscopy and biopsy. The assay was conducted before and after meals in order to assess the diagnostic value of the test together with the common liver function parameters. The greatest diagnostic sensitivity was provided by gamma glutamyl transpeptidase and bromosulfophtalein K1 clearance. In particular fasting glycocholic acid was as predictively reliable as BSF-K1. Cholylglycine levels also correlated with the prognosis of the liver disease.
Cinnamic Acid Derivatives Enhance the Efficacy of Transarterial Embolization in a Rat Model of Hepatocellular Carcinoma

Luke R Wilkins,David L Brautigan,Hanping Wu,Hooman Yarmohammadi,Ewa Kubicka,Vlad Serbulea,Norbert Leitinger,Wendy Liu,John R Haaga

DOI: https://doi.org/10.1007/s00270-016-1515-y

Abstract:Introduction: We hypothesize that the combination of transarterial embolization (TAE) plus inhibition of lactate export will limit anaerobic metabolism and reduce tumor survival compared to TAE alone. The purpose of this study was to test this hypothesis in a rat model of hepatocellular carcinoma (HCC). Methods: Rat N1-S1 hepatoma cells were assayed in vitro using the Seahorse XF analyzer to measure extracellular acidification (lactate excretion) comparing effects of the addition of caffeic acid (CA) or ferulic acid (FA) or UK-5099 with control. Monocarboxylate transporter Slc16a3 was knocked down by RNAi. N1S1 tumors were orthotopically implanted in rats and 4 groups evaluated: (1) Control, (2) TAE-only, (3) TAE plus CA, and (4) TAE plus FA. Tumor size was determined by ultrasound and analyzed by repeated measures statistics. Tumors harvested at 4 weeks were examined by microscopy. Results: Seahorse assays showed that CA and FA caused a significant reduction by >90% in lactate efflux by N1S1 tumor cells (p < 0.01). Knockdown of Slc16a3 prevented inhibition by CA. In vivo tumors grew 30-fold in volume over 4 weeks in untreated controls. By comparison, TAE resulted in near cessation of growth (10% in 4-week time period). However, both TAE + CA and TAE + FA caused a significant reduction of tumor volumes (87 and 72%, respectively) compared to control and TAE (p < 0.05). Pathologic evaluation revealed residual tumor in the TAE group but no residual viable tumor cells in the TAE + CA and TAE + FA groups. Conclusion: Addition of CA or FA enhances the effectiveness of TAE therapy for HCC in part by blocking lactate efflux.
The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study

Zheng Guo,Huabin Zhu,Xiufang Zhang,Li Huang,Xiangcai Wang,Huaqiu Shi,Li Yu,Yingwei Qiu,Fuping Tu

DOI: https://doi.org/10.3389/fonc.2022.941068

IF: 4.7

2022-09-29

Frontiers in Oncology

Abstract:Aim We sought to evaluate the efficacy and safety of conventional transcatheter arterial chemoembolization (cTACE) sequentially combined with systemic treatment by programmed cell death protein 1 (PD-1) inhibitor and anti-angiogenesis tyrosine kinase inhibitor (Anti-angiogenesis TKI) in patients with unresectable hepatocellular carcinoma (HCC). Materials and methods One hundred and forty-seven advanced HCC patients who received PD-1 inhibitors and TKIs as first-line systemic treatment between August 2019 and April 2021 were collected retrospectively. Fifty-four patients were finally included and divided into cTACE and no-cTACE groups, according to whether cTACE treatment was performed within 8 weeks before systemic treatment. The tumor objective response ratio (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared between the groups. Significant factors affecting PFS and OS were determined by Cox regression. Results Thirty-one patients received cTACE followed by systemic treatment and 23 patients received systemic treatment only. The ORRs of the cTACE group were 48.4% (after two cycles of systemic treatment) and 51.6% (after four cycles of systemic treatment), while those of the no-cTACE group were only 17.4% and 21.7%. cTACE patients also had a longer median PFS (11.70 vs. 4.00 months, P = 0.031) and median OS (19.80 vs. 11.6 months, P = 0.006) than no-cTACE patients. Regression analyses indicated that cTACE therapy and Eastern Cooperative Oncology Group performance status were independent risk factors for PFS and OS. AEs by type were similar between the cTACE and no-cTACE groups, except for liver function injury, which was more common among cTACE patients. Fourteen patients suffered with grade 1-2 of rash in 21 patients with objective response, while only 10 patients suffered with rash in 33 patients without objective response, the adjusted hazard ratio (HR) was 4.382 (1.297–14.803). Conclusions The combination of cTACE and PD-1 inhibitors and anti-angiogenesis TKIs as therapy significantly improved markers of treatment efficacy, including ORR, PFS, and OS, in unresectable HCC patients, while no more serious AEs recorded in this population compared to those receiving systemic treatment alone. Skin rash might be a predict factor to the efficacy of PD-1 inhibitors and TKI treatment.

oncology
Targeting metabolic reprogramming promotes the efficacy of transarterial chemoembolization in the rabbit VX2 liver tumor model

Yi Luo,Yong Yang,Meize Ye,Jing Zuo

DOI: https://doi.org/10.3892/ol.2024.14244

2024-01-23

Oncology Letters

Abstract:Transarterial chemoembolization (TACE) may prolong the survival of patients with hepatocellular carcinoma (HCC); however, its efficacy is limited due to the high rate of incomplete embolization. Hypoxia after embolization can cause a series of changes in the tumor microenvironment, including lactate dehydrogenase A (LDHA) upregulation. Therefore, the current study assessed the antitumor effect and the underlying mechanism of the LDHA inhibitor, sodium oxamate (Ox), combined with TACE, using the rabbit VX2 liver tumor model. VX2 liver tumor models were created in the left liver lobe of rabbits, and after 14 days of treatments, the rabbits were sacrificed for the collection of the tumor tissues and blood samples. The antitumor effects of Ox, and the combination of Ox and TACE, and changes in the tumor microenvironment after treatments were assessed by histopathological evaluation, and the safety of the treatments was analyzed by measuring changes in the serum levels of alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen and creatinine. The results demonstrated that the combination of Ox and TACE notably improved antitumor effects compared with in the other groups, as it significantly inhibited tumor growth. Additionally, treatment with Ox + TACE downregulated vascular endothelial growth factor and matrix metalloproteinase‐9, and enhanced the infiltration of CD3+ and CD8+ T cells into tumor tissues, thus suggesting that Ox + TACE may have a synergistic effect on increasing the infiltration of immune cells in the tumor microenvironment. With a well‐tolerated and manageable impairment of hepatorenal function, targeting metabolic reprogramming could promote the efficacy of TACE, thus providing novel avenues for the future clinical management of patients with advanced HCC.

oncology
Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma

Yan-Jun Xiang,Kang Wang,Hong-Ming Yu,Xiao-Wei Li,Yu-Qiang Cheng,Wei-Jun Wang,Jin-Kai Feng,Meng-Han Bo,Ying-Yi Qin,Yi-Tao Zheng,Yun-Feng Shan,Li-Ping Zhou,Jian Zhai,Shu-Qun Cheng

DOI: https://doi.org/10.1111/hepr.13773

Abstract:Aim: Transarterial chemoembolization (TACE) combined with a PD-1 inhibitor and TACE combined with a PD-1 inhibitor and lenvatinib have recently been reported as promising treatments to improve the prognosis of hepatocellular carcinoma (HCC) patients. This study aims to compare the efficacy of these two treatments. Methods: A retrospective study was conducted, and patients were recruited from two centers in China. Progression-free survival (PFS) and overall survival (OS) were compared, and the objective response rate (ORR) and disease control rate (DCR) were evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Treatment-related adverse events (AEs) were analyzed to assess safety. Results: The median follow-up for the entire cohort was 11.4 months. Of the 103 patients included in this study, 56 received triple therapy, and 47 received doublet therapy. PFS was significantly higher in the triple therapy group than in the doublet therapy group (mPFS 22.5 vs. 14.0 months, P < 0.001). Similar results were obtained in terms of OS (P = 0.001). The ORR and DCR were also better in the triple therapy group (64.3% vs. 38.3%, P = 0.010; 85.7% vs. 57.4%, P = 0.002). The most common AEs in the triple therapy group were decreased albumin (55.3%), decreased platelet count (51.8%) and hypertension (44.6%). Conclusions: The combination of TACE with a PD-1 inhibitor and lenvatinib in patients with BCLC stage B HCC might result in significantly improved clinical outcomes with a manageable safety profile compared with TACE with a PD-1 inhibitor.
Efficacy and Safety of Radiotherapy Plus Anti-Pd1 Versus Transcatheter Arterial Chemoembolization Plus Sorafenib for Advanced Hepatocellular Carcinoma: a Real-World Study

Li Jian-Xu,Deng Wen-Xiang,Huang Shi-Ting,Lin Xiao-Feng,Long Mei-Ying,Zhang Jie,Su Ting-Shi,Li,Pang Ya-Dan,Liang Chun-Feng,Zhou Hong-Mei,Lu Hai-Yan,Liang Shi-Xiong,Xiang Bang-De

DOI: https://doi.org/10.1186/s13014-022-02075-6

IF: 4.309

2022-01-01

Radiation Oncology

Abstract:Background: The combination of transcatheter arterial chemoembolization (TACE) plus sorafenib prolonged progression-free survival (PFS) and overall survival (OS) than sorafenib or TACE monotherapy for patients with hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of radiotherapy (RT) plus monoclonal antibody against programmed cell death 1 (anti-PD1) versus TACE plus sorafenib for patients with advanced HCC. Methods: Patients with advanced HCC who treated with RT plus anti-PD1 and TACE plus sorafenib were enrolled. Objective response rate (ORR), PFS, disease control rate (DCR) and OS were calculated to assess the antitumor response and the treatment-related adverse events to the safety. Results: Between January 2018 to March 2021, 37 patients underwent RT plus anti-PD1 and 41 patients underwent TACE plus sorafenib. The baseline characteristics between the two groups were comparable. The ORR and DCR were significantly higher in the RT+PD1 group than the TACE plus sorafenib group according to RECIST 1.1 (54.05% vs 12.20%, P < 0.001; 70.27% vs 46.37%, P = 0.041; respectively) and according to mRECIST (56.76% vs 31.71%, P = 0.039; 70.27% vs 46.37%, P = 0.041; respectively). RT plus anti-PD1 provided significantly better PFS (HR, 0.51; 95% CI 0.30-0.86; p=0.017) than TACE plus sorafenib. Moreover, patients with RT plus anti-PD1 had significantly higher 3-, 6-, and 9-month OS rates than those with TACE plus sorafenib(97.3% vs 92.30%, P < 0.001; 91.89% vs 68.60%, P < 0.001; 75.5% vs 60.60%, P < 0.001; respectively). The median OS was more favorable 17.4 months for the RT+PD1 group and 11.9 months for the TACE plus sorafenib group. No treatment-related death was observed. Grade 3 or more treatment-related adverse events (TRAEs) occurred significantly less in patients in the RT+PD1 group than the TACE plus sorafenib group (29.7% vs 75.6%, p < 0.001), and all TRAEs were manageable. Conclusions: In this real-world study, RT plus anti-PD1 showed significantly promising efficacy and manageable safety than TACE plus sorafenib in patients with advanced HCC. Toxicities were manageable, with no unexpected safety signals. The study provides evidence on a new therapeutic method in the treatment of advanced HCC.
Drug-eluting beads transarterial chemoembolization combined apatinib/camrelizumab for advanced hepatocellular carcinoma with hepatic arterioportal shunts

Yanqiao Ren,Bo Sun,Licheng Zhu,Lei Chen,Tao Sun,Xiangjun Dong,Chuansheng Zheng

DOI: https://doi.org/10.1093/bjr/tqae166

2024-08-27

Abstract:Objective: The objective of this study was to evaluate the efficacy and safety of drug-eluting beads transarterial chemoembolization (D-TACE) combined with apatinib/camrelizumab in advanced hepatocellular carcinoma (HCC) patients with hepatic arterioportal shunts (APS). Methods: From January 2021 to December 2022, consecutive medical records of advanced HCC patients with APS receiving D-TACE combined apatinib/camrelizumab were reviewed for eligibility. Overall survival (OS), progression-free survival (PFS), tumor response, and adverse events (AEs) were assessed. Results: A total of 23 patients were included in this study, and the median follow-up time was 11 months (range, 2-26 months). In this study, 8 patients (34.8%) achieved PR, 13 patients (56.5%) achieved SD, and 2 patients (8.7%) developed PD. The objective response rate and disease controlled rate were 34.8% and 91.3%, respectively. OS and PFS were 11 months and 7 months, respectively. Multivariate analysis indicated that tumor number was an independent prognostic factor affecting PFS. AEs occurred in 19 patients after oral apatinib and in 8 patients after camrelizumab treatment. No treatment-related death occurred. Conclusions: D-TACE combined with apatinib/camrelizumab had meaningful efficacy and controllable AEs in advanced HCC patients with APS, which may be a promising treatment option. Advances in knowledge: •1.We investigate a new treatment strategy for advanced HCC patients with hepatic arterioportal shunts；2.D-TACE combined with apatinib/camrelizumab had meaningful efficacy and controllable AEs in advanced HCC patients with APS, which may be a promising treatment option.
Pemphigus variant associated with penicillin use: a case-cohort study of 363 patients from Israel.

A. Heymann,G. Chodick,E. Kramer,Manfred S. Green,V. Shalev

DOI: https://doi.org/10.1001/ARCHDERM.143.6.704

2007-06-01

Archives of Dermatology

Abstract:OBJECTIVE To determine whether medication use is associated with the development of a pemphigus variant. DESIGN Population-based case-cohort study. SETTING Health maintenance organization in Israel. METHODS All incident pemphigus variant cases diagnosed from January 1, 1997, through December 31, 2001, among 1.5 million members were identified. A cohort of 150,000 was randomly selected from the health maintenance organization population as the control group. Data on case patients and control subjects, including all medication purchased during the 6 months before the diagnosis, were obtained using the health maintenance organization's central database. RESULTS We identified a total of 363 case patients diagnosed as having pemphigus during the 5-year study (6,961,853 person-years of follow-up). The mean age at diagnosis was 49.8 (SD, 22.7) years, and 53% of the cases were women. Results of a multivariate analysis showed that increased risk for pemphigus was associated with purchasing penicillin during the 6 months before the diagnosis (odds ratio, 2.03; 95% confidence interval, 1.56-2.64). Compared with individuals with no penicillin purchases, we calculated increased risks of 1.84 (95% CI, 1.36-2.49) and 3.02 (95% CI, 1.41-6.49) in those with 1 and 3 or more purchases, respectively. None of the other examined medications, including cephalosporins, angiotensin-converting enzyme inhibitors, dipyrone, anticonvulsants, and nonsteroidal anti-inflammatory drugs, showed similar risks. CONCLUSIONS To our knowledge, the present research is one of the largest published epidemiological studies on pemphigus variant. The use of computerized medical and administrative databases allowed the detection of case patients in the community, resulting in a higher calculated incidence rate than previously reported. The findings suggest a relationship between the use of penicillin and pemphigus variant. Further studies to assess the nature of this statistical association are warranted.
Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study

Lingzhan Meng,Hu Li,Yingjie Ji,Peng Yu,Zizheng Wang,Li Cao,Bin Shi,Yanling Shao,Jin Yan,Yinjie Gao,Zhenyu Zhu

DOI: https://doi.org/10.1007/s00262-024-03857-5

IF: 6.63

2024-11-07

Cancer Immunology Immunotherapy

Abstract:The integration of transarterial chemoembolization (TACE) with systemic therapy has demonstrated improved survival outcomes in patients with unresectable hepatocellular carcinoma (HCC). However, there is limited evidence evaluating the combination of TACE with the systemic regimen of anti-PD-1/L1 inhibitor plus lenvatinib. This study aims to assess the efficacy and safety of TACE combined with lenvatinib and sintilimab in unresectable HCC patients.

oncology,immunology
The Efficacy and Safety of Transarterial Chemoembolization Combined with Cadonilimab and Lenvatinib for Unresectable Hepatocellular Carcinoma: A Phase II Clinical Trial.

Guo Liang,Shanzhi Gu,Yabing Guo,Hailiang Li,Jingfeng Liu,Jibing Liu,Ming Huang,Yinghua Zou,Luke Huang,Yangyang Zhang,Ting Liu,Wei Liu,Zhongmin Wang,Baiyong Li,Yu Xia

DOI: https://doi.org/10.1200/jco.2024.42.3_suppl.478

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:478 Background: Immune-checkpoint inhibitors, in combination with targeted therapy and local therapy, have been developed as promising treatment for unresectable hepatocellular carcinoma (uHCC) of intermediate stage. This study aimed to assess the efficacy and safety of cadonilimab(a tetravalent PD-1/CTLA-4 bispecific antibody) plus Lenvatinib (Len) and transarterial chemoembolization (TACE) in the treatment of intermediate HCC. Methods: This open label, multicenter phase II trial enrolled patients with histologically or clinically confirmed intermediate uHCC to receive TACE followed by cadonilimab 10mg/kg every 3 weeks plus Len until disease progression or intolerable toxicity. The primary endpoint was progression free disease (PFS) according to RECIST v1.1. The secondary endpoint includes safety, overall survival (OS), PFS according to modified RECIST (mRECIST), and objective response rate (ORR), disease control rate (DCR) and duration of response (DoR) by both RECIST v1.1 and mRECIST. Results: From June 2022 to May 2023, 78 patients were screened and 60 patients enrolled. As of August 15, 2023, 60 patients received at least once cadonilimab and the median duration of follow-up was 5.1 months. The average number of TACE procedures per patient was 1.70. The median PFS and OS were not reached, while the 6-month PFS rate was 77.1% (95% CI, 60.8-87.3) per RECIST v1.1 and 75.6% (95% CI, 59.5-86.0) per mRECIST. The ORR and DCR were 35.0% (95% CI, 23.1-48.4) and 96.7% (95% CI, 88.5-99.6) according to RECIST v1.1 and 85.0% (95% CI, 73.4-92.9) and 95.0% (95% CI, 86.1-99.0) according to mRECIST. 9 patients (15.0%) achieved complete response per mRECIST. The incidence of grade≥3 treatment-related adverse events (TRAEs) was 68.9%. The incidence of grade≥3 adverse events related to cadonilimab was 45.9%.The most common TRAEs included thrombocytopenia, aspartate aminotransferase increased, and alanine aminotransferase increased. Conclusions: Combination of TACE and cadonilimab plus len showed promising efficacy and manageable toxicity in intermediate uHCC. Benefit of control on tumor progression after TACE and lasting survival can be expected. Clinical trial information: NCT05319431 . [Table: see text]
The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

Fei Cao,Yi Yang,Tongguo Si,Jun Luo,Hui Zeng,Zhewei Zhang,Duiping Feng,Yi Chen,Jiaping Zheng

DOI: https://doi.org/10.3389/fonc.2021.783480

IF: 4.7

2021-12-20

Frontiers in Oncology

Abstract:Objective To assess the efficacy and safety of transarterial Chemoembolization (TACE) combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma (HCC). Patients and Methods The data of patients with unresectable HCC administered a combination therapy with TACE and lenvatinib plus sintilimab were retrospectively assessed. Patients received lenvatinib orally once daily 2 weeks before TACE, followed by sintilimab administration at 200 mg intravenously on day 1 of a 21-day therapeutic cycle after TACE. The primary endpoints were objective response rate (ORR) and duration of response (DOR) by the modified RECIST criteria. Results Median duration of follow-up was 12.5 months (95%CI 9.1 to 14.8 months). ORR was 46.7% (28/60). Median DOR in confirmed responders was 10.0 months (95%CI 9.0-11.0 months). Median progression-free survival (PFS) was 13.3 months (95%CI 11.9-14.7 months). Median overall survival (OS) was 23.6 months (95%CI 22.2-25.0 months). Conclusions TACE combined with lenvatinib plus sintilimab is a promising therapeutic regimen in unresectable hepatocellular carcinoma.

oncology
Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8+T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model

Shen Zhang,Lin Xu,Jia-Qing Li,Ming-Zhan Du,Yu Yin,Bin-Yan Zhong,Han-Si Liang,Wan-Ci Li,Cai-Fang Ni,Xiao-Li Zhu

DOI: https://doi.org/10.1007/s00270-024-03813-x

2024-08-05

Abstract:Purpose: To investigate the influence of transarterial embolization (TAE) on programmed cell death-ligand 1(PD-L1) expression and CD8+T tumour infiltrative lymphocyte cytotoxicity in the Sprague-Dawley (SD) rat model of hepatocellular carcinoma (HCC). Materials and methods: An orthotopic HCC model was established in twenty SD rats treated with TAE (lipiodol, n = 10) or sham (normal saline, n = 10) using homologous N1S1 hepatoma cells. Rats were euthanized 1 week after embolization. Flow cytometry was used to assess the proportion of CD4+T, CD8+T and programmed cell death-1+(PD-1+) CD8+T lymphocytes in the spleens and tumours. Distribution of CD8+T, granzyme-B+CD8+T lymphocytes and PD-L1+ cells was assessed by immunohistochemistry (IHC) or multiplex IHC. p value < 0.05 was considered statistically significant. Results: The CD4/CD8 ratio and PD-1+CD8+ T lymphocytes exhibited higher values in TAE-treated tumours compared to sham-treated tumours (p = 0.021 and p = 0.071, respectively). Conversely, the number of CD8+T lymphocytes was decreased in TAE-treated tumours (p = 0.043), especially in the central region (p = 0.045). However, more CD8+T lymphocytes were found infiltrating the marginal region than central region in TAE-treated tumours (p = 0.046). The proportion of granzyme-B+CD8+T lymphocytes and the PD-L1 positive areas was elevated in tumours that treated with TAE (p all < 0.05). There was a negative correlation between PD-L1 expression and the number of infiltration of CD8+ T lymphocytes (p = 0.036). Conclusions: Immune cells are distributed unevenly in the tumours after TAE. The intrinsic induction state of the tumour after embolization may be insufficient to elicit a maximal response to PD-1/PD-L1 inhibitors.
Celecoxib and cisplatin dual-loaded microspheres synergistically enhance transarterial chemoembolization effect of hepatocellular carcinoma

Kunpeng Wu,Shengnan Ma,Xiaohong Xu,Yiming Liu,Chuan Tian,Chengzhi Zhang,Jiheng Shan,Zongming Li,Kewei Ren,Jianzhuang Ren,Xinwei Han,Yanan Zhao

DOI: https://doi.org/10.1016/j.mtbio.2023.100927

IF: 8.2

2023-12-31

Materials Today Bio

Abstract:Transarterial chemoembolization (TACE) is a first-line treatment for intermediate to advanced-stage liver cancer, with drug-eluting microspheres commonly used as embolic agents. However, currently available drug-eluting microspheres suffer from low drug-loading capacity and limited drug options. In this work, we developed polydopamine-modified polyvinyl alcohol dual-drug-loaded microspheres encapsulating celecoxib and cisplatin (referred to as PCDMS). Physicochemical characterization revealed that the surface of the microspheres displayed increased roughness after polydopamine modification, and celecoxib and cisplatin were successfully loaded onto the microsphere surface. In vitro cell experiments demonstrated that the PCDMS significantly inhibited the proliferation and migration of highly metastatic human liver cancer cells (MHCC-97H) and human liver cancer cells (SMMC-7721). Furthermore, the dual-loaded microspheres exhibited remarkable tumor growth inhibition and reshaped the tumor microenvironment in both subcutaneous H22 liver cancer model in Balb/c mice and intrahepatic VX2 tumor model in New Zealand rabbits, demonstrating a synergistic antitumor effect where 1 + 1>2. This work provides a potential therapeutic approach for the treatment of refractory liver cancer and holds significant translational potential.

engineering, biomedical,materials science, biomaterials
Ultrasound-guided RNA Interference Targeting HIF-1 Alpha Improves the Effects of Transarterial Chemoembolization in Rat Liver Tumors

Cheng-Shi Chen,Qing Zhao,Sheng Qian,Hai-Liang Li,Chen-Yang Guo,Wei Zhang,Zhi-Ping Yan,Rong Liu,Jian-Hua Wang

DOI: https://doi.org/10.2147/ott.s94800

IF: 4

2015-01-01

OncoTargets and Therapy

Abstract:Aim: To investigate whether ultrasound-guided RNA interference (RNAi) targeting hypoxiainducible factor-1alpha (HIF-1 alpha) can enhance the efficacy of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma.Materials and methods: Rats with orthotopic hepatocellular carcinoma were randomized to four groups and treated as follows: 1) control; 2) siHIF-1 alpha; 3) TACE; 4) siHIF-1 alpha+TACE. Lentivirus (4x10(8) transfection units) with or without small interfering RNA (siRNA) expression in 0.6 mL transduction reagent was injected into tumors using a standard 1 mL syringe under ultrasonic guidance. In the siHIF-1 alpha+TACE and siHIF-1 alpha groups, rats received siRNA-expressing lentivirus; the rats in the TACE and control groups received lentivirus without siRNA. TACE was performed by placing a microcatheter into the gastroduodenal artery.Results: The median survival time, body weight, and tumor volume of the siHIF-1 alpha+TACE group were better than those of the TACE, siHIF-1 alpha, and control groups. A comparative analysis of the different treatment groups demonstrated that HIF-1 alpha RNAi could downregulate the levels of HIF-1 alpha and VEGF, inhibit tumor angiogenesis, and lessen metastases; all of these effects were enhanced by TACE.Conclusion: HIF-1 alpha RNAi, which was administered in vivo in liver tumors under ultrasound guidance, improved the efficacy of TACE in treating hepatocellular carcinoma in an animal model.

CXCR4 antagonist AMD3100 enhances therapeutic efficacy of transcatheter arterial chemoembolization in rats with hepatocellular carcinoma

Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist AMD3100 in a Mouse Transplantation Model

Enhanced Efficacy of Direct Immunochemotherapy for Hepatic Cancer with Image-Guided Intratumoral Radiofrequency Hyperthermia

Effect of inhibit or AMD3100 of CXCR4 on liver metastasis of colorectal cancer

CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation

Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models

AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression

[Serum cholylglycine in the evaluation of impaired hepatic function].

Cinnamic Acid Derivatives Enhance the Efficacy of Transarterial Embolization in a Rat Model of Hepatocellular Carcinoma

The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study

Targeting metabolic reprogramming promotes the efficacy of transarterial chemoembolization in the rabbit VX2 liver tumor model

Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma

Efficacy and Safety of Radiotherapy Plus Anti-Pd1 Versus Transcatheter Arterial Chemoembolization Plus Sorafenib for Advanced Hepatocellular Carcinoma: a Real-World Study

Drug-eluting beads transarterial chemoembolization combined apatinib/camrelizumab for advanced hepatocellular carcinoma with hepatic arterioportal shunts

Pemphigus variant associated with penicillin use: a case-cohort study of 363 patients from Israel.

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study

The Efficacy and Safety of Transarterial Chemoembolization Combined with Cadonilimab and Lenvatinib for Unresectable Hepatocellular Carcinoma: A Phase II Clinical Trial.

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8+T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model

Celecoxib and cisplatin dual-loaded microspheres synergistically enhance transarterial chemoembolization effect of hepatocellular carcinoma

Ultrasound-guided RNA Interference Targeting HIF-1 Alpha Improves the Effects of Transarterial Chemoembolization in Rat Liver Tumors